Skip to main content
Erschienen in: Annals of Hematology 10/2014

01.10.2014 | Letter to the Editor

The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

verfasst von: K. T. Htun, J. McFadyen, H. A. Tran

Erschienen in: Annals of Hematology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
2.
Zurück zum Zitat Parameswaran R, Shapiro AD, Gill JC et al (2005) Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11:100–106PubMedCrossRef Parameswaran R, Shapiro AD, Gill JC et al (2005) Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11:100–106PubMedCrossRef
3.
Zurück zum Zitat Warkentin TE, Margetts P, Connolly SJ et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 1 119:2172–2174CrossRef Warkentin TE, Margetts P, Connolly SJ et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 1 119:2172–2174CrossRef
4.
Zurück zum Zitat Hoffman M, Volovyk Z, Monroe D (2013) Reversal of dabigatran effects by factor VIIa in a cell-based model of coagulation. ISTH 2013, Abstract in JTH, XXIV ISTH Congress Hoffman M, Volovyk Z, Monroe D (2013) Reversal of dabigatran effects by factor VIIa in a cell-based model of coagulation. ISTH 2013, Abstract in JTH, XXIV ISTH Congress
5.
Zurück zum Zitat Khoo TL, Weatherburn C, Kershaw G et al (2013) The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 35:222–224PubMedCrossRef Khoo TL, Weatherburn C, Kershaw G et al (2013) The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 35:222–224PubMedCrossRef
6.
Zurück zum Zitat Hapgood G, Butler J, Malan E et al (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315PubMedCrossRef Hapgood G, Butler J, Malan E et al (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315PubMedCrossRef
7.
Zurück zum Zitat Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
8.
Zurück zum Zitat Makris M, Van Veen JJ, Tait CR et al (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160:35–46PubMedCrossRef Makris M, Van Veen JJ, Tait CR et al (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160:35–46PubMedCrossRef
Metadaten
Titel
The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa
verfasst von
K. T. Htun
J. McFadyen
H. A. Tran
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 10/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2039-7

Weitere Artikel der Ausgabe 10/2014

Annals of Hematology 10/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.